NASDAQ$RARE
Ultragenyx Pharmaceutical Inc. · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Ultragenyx reported Q4 2020 financial results and provided a corporate update.
Ultragenyx reported total revenue of $91.5 million for the fourth quarter of 2020. The company had a net loss of $24.0 million, or $0.37 per share. They reaffirmed the 2021 guidance range for Crysvita of $180 million to $190 million.
- Total revenue for the fourth quarter of 2020 was $91.5 million.
- Crysvita revenue in Ultragenyx territories was $40.4 million for Q4 2020.
- Dojolvi product sales were $6.4 million in the fourth quarter of 2020.
- Net loss for the fourth quarter of 2020 was $24.0 million, or $0.37 per share.
Headline financials
Revenue & EPS history
Ultragenyx · Revenue · Quarterly
$91.5M
Revenue by segment
Ultragenyx · $50.5M total across 3 segments · Q4 2020
- Crysvita Revenue$40.4M+35.1%80.0%
- Dojolvi Revenue$6.4M—12.7%
- Mepsevii Revenue$3.7M-15.9%7.3%
Forward guidance
The company reaffirms the 2021 guidance range for Crysvita that was provided at the beginning of the year. This range is $180 million to $190 million for the North American profit share region and the other regions where product sales are recognized (Latin America and Turkey).
Tailwinds
- Initiate a Phase 3 study for DTX401 for Glycogen Storage Disease Type Ia (GSDIa) in the first half of 2021.
- Initiate a Phase 3 study for DTX301 for Ornithine Transcarbamylase (OTC) Deficiency in the second half of 2021.
- Initiate a Phase 1/2/3 study for UX701 for Wilson disease in the first half of 2021.
- Resume enrollment and dosing in the Phase 1/2 study for GTX-102 for Angelman Syndrome in the first half of 2021.
- Conduct a Phase 2/3 study in pediatric patients for UX143 (setrusumab) for Osteogenesis Imperfecta, anticipated in second half of 2021.
Headwinds
- Uncertainty and potential delays related to clinical drug development.
- Smaller than anticipated market opportunities for the company’s products and product candidates.
- Manufacturing risks.
- Competition from other therapies or products.
- Effects from the COVID-19 pandemic on the company’s clinical activities, business and operating results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
20 / 48 earnings
Positive
+14.7%
Q1 2015
Best reaction
-18.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +5.2% | -12.5% | |
| Q4 2025 | -12.7% | -13.0% | -9.2% | |
| Q3 2025 | -1.5% | -1.6% | +12.1% | |
| Q1 2025 | -4.8% | +2.9% | +6.0% | |
| Q4 2024 | -2.4% | +1.8% | -9.6% | |
| Q3 2024 | -1.1% | -1.4% | -7.3% | |
| Q2 2024 | +12.1% | +10.6% | +26.1% | |
| Q1 2024 | -1.3% | -3.1% | -7.3% | |
| Q4 2023 | +7.1% | +4.8% | +3.7% | |
| Q3 2023 | +7.7% | +5.7% | +11.4% | |
| Q2 2023 | -11.1% | -16.9% | -10.8% | |
| Q1 2023 | +9.0% | +8.6% | +17.4% | |
| Q4 2022 | +10.2% | +2.9% | -12.8% | |
| Q3 2022 | -9.0% | -16.4% | -4.2% | |
| Q2 2022 | +4.9% | +0.9% | -2.6% | |
| Q1 2022 | -18.9% | -24.5% | -27.5% | |
| Q4 2021 | -2.5% | -1.6% | -12.5% | |
| Q3 2021 | +0.0% | -3.1% | -8.0% | |
| Q2 2021 | +4.9% | +10.9% | +24.8% | |
| Q1 2021 | -0.5% | +7.5% | -11.4% | |
| Q4 2020 | -10.1% | -13.7% | -24.1% | |
| Q3 2020 | +4.1% | +10.1% | +31.3% | |
| Q2 2020 | +2.5% | +10.4% | +12.4% | |
| Q1 2020 | -2.4% | +4.1% | +8.1% | |
| Q4 2019 | -2.8% | -2.8% | -31.1% | |
| Q3 2019 | -7.9% | -4.6% | +5.0% | |
| Q2 2019 | -7.6% | -3.6% | -9.6% | |
| Q1 2019 | -8.0% | -5.7% | -15.4% | |
| Q4 2018 | +6.8% | +5.6% | +21.9% | |
| Q3 2018 | +0.9% | -3.0% | -6.4% | |
| Q2 2018 | -9.5% | -2.5% | +6.8% | |
| Q1 2018 | +6.1% | +17.7% | +42.3% | |
| Q4 2017 | -1.7% | +1.6% | +9.0% | |
| Q3 2017 | +3.2% | -5.2% | +7.7% | |
| Q2 2017 | -5.4% | -10.6% | -27.4% | |
| Q1 2017 | +2.0% | +2.5% | -5.1% | |
| Q4 2016 | +0.2% | +0.2% | +10.2% | |
| Q2 2016 | -2.2% | +0.2% | +2.5% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | -0.7% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | +14.7% | — | — | |
| Q4 2014 | -7.2% | — | — | |
| Q3 2014 | -4.2% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q4 2013 | -8.4% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro